Cytogen, Inc. (KOSDAQ:217330)

Market Cap	207.40B
Revenue (ttm)	25.09B
Net Income (ttm)	-15.23B
Shares Out	23.07M
EPS (ttm)	-660.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,101,405
Average Volume	1,683,843
Open	9,610.00
Previous Close	8,910.00
Day's Range	8,920.00 - 9,700.00
52-Week Range	2,260.00 - 10,550.00
Beta	-0.20
RSI	79.71
Earnings Date	Nov 21, 2025

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 217330

Financial Performance

In 2024, Cytogen's revenue was 10.91 billion, an increase of 242.63% compared to the previous year's 3.18 billion. Losses were -17.12 billion, 8.54% more than in 2023.